Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
US11965031B2 · kind B2 · utility
0Cited by
29References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 16, 2020 |
| Grant date | Apr 23, 2024 |
| Priority date | — |
| Expiry date | Jul 25, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.